Immunomedics — Proxy Contest (February 2017)
23 slides from Immunomedics's proxy contest presentation, Feb 10, 2017
Slide 1: Immunomedics Announces Exclusive Global Licensing Agreement with Seattle Genetics
IMMUNOMEDICS, INC. Advanced Antibody - Based Therapeutics Oncology Autoimmune Diseases February 10, 2017 Immunomedics Announces Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan ( IMMU - 132 ) in Multiple Indications Worldwide
Slide 2: Important Additional Information / Forward Looking Statements
Important Additional Information / Forward Looking Statements 2 Important Additional Information Immunomedics, Inc. (the “Company”), its directors and certain of its executive officers will be deemed to be participants in the solicitation of proxies from Company stockholders in connection with the m
Slide 3: Overview
3 Overview
Slide 4: Overview of Terms
Overview of Terms 4 Transaction Summary • Seattle Genetics will develop, fund, manufacture and commercialize IMMU - 132, Immunomedics’ proprietary solid tumor therapy candidate, in multiple indications worldwide Total Consideration • The agreement provides for potential payments of approximately $2
Slide 5: Overview of Terms (cont.)
Overview of Terms (cont.) 5 Equity Investment • Up to a 9.9 % stake • Purchasing 3,000,000 shares of common stock, representing an approximately 2.8% stake in Immunomedics , at a per share price of $4.90, which represents a 10% premium to Immunomedics ’ 15 trading day VWAP of $4.45 • Three - year wa
Slide 6: Seattle Genetics Assuming Rights to Develop, Fund, Manufacture & Commercialize IMMU-132
Seattle Genetics Assuming Rights to Develop, Fund, Manufacture & Commercialize IMMU - 132 • Agreement provides for Seattle Genetics to develop, fund, manufacture & commercialize IMMU - 132 in multiple indications • Immunomedics will retain the right to elect to co - promote IMMU - 132 in the United
Slide 7: Seattle Genetics agreement: indications and path to approval for IMMU-132
• Seattle Genetics is an industry leader in developing and commercializing antibody - drug conjugates (ADCs) • Agreement with Seattle Genetics includes multiple indications for IMMU - 132, including: – Triple - negative breast cancer (TNBC) – Urothelial cancer (UC) – Small - cell lung cancer (SCLC)
Slide 8: Seattle Genetics
8 Seattle Genetics
Slide 9: Seattle Genetics company profile
• Global headquarters in Bothell, Washington • Traded on Nasdaq Stock Market under the symbol SGEN • More than 900 employees • Industry leader in ADCs — technology designed to harness the targeting ability of antibodies to deliver cell - killing agents directly to cancer cells • Has one marketed liq
Slide 10: Why Seattle Genetics is the right partner for IMMU-132
• Seattle Genetics has a reputation as one of the most successful and financially strong standalone ADC companies – E xpertise in clinical development, regulatory activities, manufacturing and commercialization of ADCs makes Seattle Genetics ideally suited to advance IMMU - 132 program globally • Ag
Slide 11: Implications for Immunomedics
11 Implications for Immunomedics
Slide 12: What Does This Deal Mean for Immunomedics?
What Does This Deal Mean for Immunomedics? 1. Per share value of the $250 million upfront cash payment is $ 2.12 per share 3,4 2. Risk - adjusted pre - tax NPV (base case) of contingent payments: $9.40 per share 3,4 – Successful combinations with checkpoint and PARP inhibitors could make IMMU - 132
Slide 13: Our Development Pipeline is Advanced, Robust & Promising
Our Development Pipeline is Advanced, Robust & Promising 13 Therapy Treatment Purpose Phase 3 Epratuzumab (humanized anti - CD22) Pediatric acute lymphoblastic leukemia* Phase 2 Labetuzumab govitecan/ IMMU - 130 (anti - CEACAM5 - SN - 38 antibody - drug conjugate) Metastatic colorectal cancer Veltuz
Slide 14: Strategic Process
14 Strategic Process
Slide 15: Original Strategic Process
Original Strategic Process • A financial advisor was retained in December 2015 – Mandate to explore an out - licensing deal only – Board and financial advisor conducted outreach to 30 parties, 22 signed NDAs and were in different levels of due diligence – Made progress and received non - binding ter
Slide 16: Greenhill & Co. Process
Greenhill & Co. Process • Greenhill & Co. was retained in September 2016 on the basis of its reputation and global capabilities in biopharma M&A and licensing transactions – Given a broader mandate by the Board to explore a range of strategic and business opportunities, including licensing or sale o
Slide 17: Depth of Diligence
Depth of Diligence Clinical CMC Regulatory IP Commercial • 110+ page detailed clinical deck • Detailed data was made available in data room • Access to the Company’s raw clinical data/database was made available • Multiple rounds of Q&A (both written responses & calls) • On - site visits for review
Slide 18: Overall Process
Overall Process • Immunomedics’ process and intent were very public over 13 months – Investor R&D Day on January 18, 2017 made public the latest clinical data for IMMU - 132 and detailed CMC and regulatory updates • Over 45 parties contacted with 33 parties receiving detailed diligence information u
Slide 19: Transaction Committee Process
19 Transaction Committee Process
Slide 20: Transaction Committee Process
Transaction Committee Process • Greenhill & Co. reported to the Transaction Committee of the Board – Transaction Committee consists of the five independent Board members • Transaction Committee kept apprised of outreach program and approach – Involved in negotiating term sheets and contracts • On ti
Slide 21: Out-licensing vs. Commercializing Internally
Out - licensing vs. Commercializing Internally • Research & development (R&D) is Immunomedics’ core c ompetency, not commercialization • Company has no commercial infrastructure in the United States – Immunomedics would need to build a commercial arm from scratch, including marketing, sales, logisti
Slide 22: Use of Proceeds
Use of Proceeds • Upon closing of the transaction, the Company will evaluate: – Priority of clinical programs – Long - and short - term funding needs – A budget for the remainder of 2017 – Potential tax - efficient ways to return capital to stockholders • Overall, this transaction supports the Compa
Slide 23: Transaction Summary
Transaction Summary • Agreement provides for potential payments of approximately $2 billion, plus royalties – $250 million upfront cash to Immunomedics for U.S., Canada and EU rights – Additional $50 million or designated economic split on rights relating to territories outside the U.S., Canada and